ALGS

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases. Headquartered in South San Francisco, California, the company advances a pipeline of targeted antiviral and liver-focused medicines, with particular emphasis on chronic hepatitis B (CHB) and coronaviruses. Aligos operates through two primary therapeutic platforms: its virology platform targeting chronic viral infections and its NASH (nonalcoholic steatohepatitis) platform addressing liver disease. The company's lead product candidates include ALG-010133, a small interfering RNA (siRNA) therapy, and ALG-000184, a capsid assembly modulator, both designed for CHB treatment. Aligos also develops S-cleavage activating polymers (SCAMPs) and antisense oligonucleotides (ASOs) as part of its multi-pronged approach to achieving functional cures for chronic hepatitis B. The company went public in October 2020 through an initial public offering on the Nasdaq Global Select Market under ticker symbol ALGS. In recent developments, Aligos has advanced multiple clinical trials evaluating combination therapies for CHB and continues to refine its coronavirus antiviral programs. The company collaborates with various research institutions and maintains strategic partnerships to accelerate its drug development efforts while operating research facilities in both the United States and Asia.